Regulatory approval

Published by the Health Service Executive. Approved

Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab - ODMS; Docetaxel, Trastuzumab - N/A

Citation

Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle, 2025, version number 11, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6545/204_v11_PertuzumabTrasDoc.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-02-01	Health Service Executive	Indication approved for reimbursement.